Despite the increased attention is currently paid to cancer immunotherapy (especially, treatments targeting PD-1/PD-L1 molecules) – which may become the standard of care in treating all unresectable stage III and IV melanomas, regardless of the BRAF mutational status, we here focused on molecular mechanisms involved in development and progression of the disease. This evidence concerns the gene BRAF and melanoma.